ClinicalTrials.gg
CompletedNCT02130024RIVALUpdated Jun 5, 2019Results posted

A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients

A Phase 4 interventional study of Ranibizumab 0.5 mg and Aflibercept 2.0 mg in Age-Related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 22 sites in Australia. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-06-05.

Primary conditionGeographic AtrophyRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Geographic Atrophy
Why
  1. The study's title name Geographic Atrophy, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
281
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Geographic Atrophy by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Geographic Atrophy · Novartis.

Enrollment
4th of 15
281 · median 158
Started
2014
with 1 other
Phase 4
6 of 15
none open now
Registered
4th of 15
by date

Among the 15 studies in Geographic Atrophy by Novartis, this one is the 4th largest by enrollment, is one of 2 that started in 2014, is one of 6 in phase 4, and was the 4th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

1 of the 15 studies in Geographic Atrophy by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Geographic Atrophy by Novartis, or all of them as a file.
02

Study summary

The purpose of this study was to compare the development of new geographic atrophy in patients with wet Age-related Macular Degeneration (AMD) when treated with either ranibizumab or aflibercept over 24 months. Geographic atrophy is an advanced form of AMD that can result in the progressive and irreversible loss of visual function over time.

Read the detailed description

In each arm, patients underwent three monthly loading doses (at Baseline, Week 4, and Week 8). From Week 8, after the patient had received their third injection of study treatment, the visit intervals were determined by the patient's disease activity. If any of the protocol-specified signs of disease activity were present in the study eye, the subsequent injection visit interval was kept at 4 weeks. If none of the signs were present, the subsequent injection interval was extended by 2-week increments up until a maximum of 12-weekly intervals was reached. If there were any signs of disease activity in the study eye, the treatment interval was reduced as specified in the protocol. The planned individual duration of study participation was 24 months.

03

Conditions studied

  • Age-Related Macular Degeneration

Browse trials for

Keywords

  • Age-related macular degeneration
  • AMD
  • wet AMD
  • ranibizumab
  • aflibercept
  • geographic atrophy
  • inject and extend
04

In context

Geographic Atrophy Reclassified

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

This study's enrollment of 281 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.

Browse Geographic Atrophy studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Geographic Atrophy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria:

  • Written .

Inclusion criteria specific to the study eye:

  • Diagnosis of active subfoveal Choroidal Neovascularisation (CNV) secondary to wet Age-related Macular Degeneration (AMD);
  • Best Corrected Visual Acuity (BCVA) score of 23 letters or more as measured by 3-metre Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts.

Exclusion criteria:

  • Pregnant, nursing, or at risk of becoming pregnant during the study;
  • Inability to comply with the study or follow-up procedures;
  • Recent (3 months) stroke or myocardial infarction; uncontrolled hypertension; to the study treatments or to fluorescein;
  • In either eye: active periocular or ocular infection or inflammation; iris neovascularisation; uncontrolled or neovascular glaucoma; or one or more patch of geographic atrophy (GA) as specified in the protocol.

Exclusion criteria specific to the study eye:

  • Prior or current treatment with anti-angiogenic drugs or ;
  • Other eye conditions as specified in the protocol;
  • Any intraocular procedure carried out within 2 months before baseline or anticipated within 6 months following baseline.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
281 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.5 mg

    3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity \[treat and extend\]

    Drug: Ranibizumab 0.5 mg

  • Active comparator
    Aflibercept 2.0 mg

    3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity \[treat and extend\]

    Drug: Aflibercept 2.0 mg

Interventions

07

What researchers measure

Primary outcomes

  1. Mean Change in Square-root Area of Geographic Atrophy (GA) From Baseline to Month 24

    Multimodal images of the eye were obtained by trained study site personnel and forwarded to an independent Central Reading Center, where the area of GA was measured. Area was treated as zero if GA was reported as absent (Overall determination of GA presence). Mean change from baseline in GA area was reported in square root-transformed data (mm). One eye (study eye) contributed to the analysis.

    Time frame: Baseline, Month 24

Secondary outcomes

  1. Mean Change in Square-root Area of Geographic Atrophy From Baseline to Month 12

    Multimodal images of the eye were obtained by trained study site personnel and forwarded to an independent Central Reading Center, where the area of GA was measured. Area was treated as zero if GA was reported as absent (Overall determination of GA presence). Mean change from baseline in GA area was reported in square root-transformed data (mm). One eye (study eye) contributed to the analysis.

    Time frame: Baseline, Month 12

  2. Percentage of Patients With Newly Developed Geographic Atrophy During the Overall 24 Months of the Study

    Multimodal images of the eye were obtained by trained study site personnel and forwarded to an independent Central Reading Center. A patient was considered to have developed new GA if they did not have any GA at the start of the study period and were subsequently diagnosed with GA during the study period (diagnosis of GA change from "No" to "Yes)." The analysis of new GA development was restricted to only those subjects without GA reported at baseline. One eye (study eye) contributed to the analysis.

    Time frame: Baseline, Month 12, Month 24

  3. Mean Number of Intravitreal Injections From Baseline to Month 12 and to Month 24

    The number of intravitreal injections was calculated. One eye (study eye) contributed to the analysis.

    Time frame: Baseline, Month 12, Month 24

  4. Mean Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12 and to Month 24

    Visual acuity was assessed with spectacles or other visual corrective devices in place using logMAR charts and recorded in number of letters correctly identified. BCVA change was defined as a change in letters correctly identified from the baseline assessment. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis

    Time frame: Baseline, Month 12, Month 24

  5. Mean Change in Central Subfield Foveal Thickness (CSFT) From Baseline to Month 12 and to Month 24

    CSFT (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using Optical Coherence Tomography (OCT) and measured in micrometers. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis

    Time frame: Baseline, Month 12, Month 24

  6. Percentage of Patients Showing no Intraretinal Fluid (IRF)/Subretinal Fluid (SRF)

    Intraretinal fluid and subretinal fluid was assessed using Optical Coherence Tomography (OCT) and recorded as Present/Absent. One eye (study eye) contributed to the analysis.

    Time frame: Month 2, Month 12, Month 24

  7. Percentage of Patients Showing Greater Than and Equal to 15 Letters Gain for BCVA From Baseline to Month 12 and to Month 24

    Visual acuity was assessed with spectacles or other visual corrective devices in place using logMAR charts and recorded in number of letters correctly identified. A gain in letters correctly identified indicates an improvement in visual acuity, while a loss indicates a worsening. One eye (study eye) contributed to the analysis.

    Time frame: Baseline, Month 12, Month 24

  8. Percentage of Patients Showing Less Than and Equal to 15 Letters Loss for BCVA From Baseline to Month 12 and to Month 24

    Visual acuity was assessed with spectacles or other visual corrective devices in place using logMAR charts and recorded in number of letters correctly identified. A gain in letters correctly identified indicates an improvement in visual acuity, while a loss indicates a worsening. One eye (study eye) contributed to the analysis.

    Time frame: Baseline, Month 12, Month 24

  9. Mean Number of Times a Patient Needed to Return to Monthly Intravitreal Injections Over 24 Months

    The number of times the patient returned to a monthly injection interval (from an extended interval) at least once during the 24-month study was calculated. One eye (study eye) contributed to the analysis.

    Time frame: Month 24

  10. Mean Change in Vascular Endothelial Growth Factor (VEGF) Plasma Concentration From Baseline to 7 Days After the Second and 7 Days After the Third Mandated Intravitreal Injection of Treatment

    Blood for VEGF plasma concentration analysis was collected at Baseline and again at 7 days after the injection at Week 4 and 7 days after the injection at Week 8.

    Time frame: Baseline, Week 5, Week 9

  11. Percentage of Patients With Change in Retinal Nerve Fibre Thickness From Baseline to Month 12 and Month 24

    Retinal nerve fibre thickness was assessed using Optical Coherence Tomography (OCT) and measured in micrometers. A negative change in value (i.e. thinner nerve fibre) indicates nerve damage. One eye (study eye) contributed to the analysis.

    Time frame: Baseline, Month 12, Month 24

  12. Percentage of Patients With Ocular Inflammation at Baseline and 7 Days Post-injection Following 3rd Mandated Intravitreal Injection - Anterior Chamber Cells

    Anterior cell grade was assessed by the Investigator during slit lamp examination and graded on a 5-point scale: Grade 0=0 cells; Grade 1=1 to 10 cells; Grade 2=11 to 20 cells; Grade 3=21 to 50 cells; Grade 4=\>50 cells. The presence of blood cells (red and white) in the anterior chamber of the eye (the fluid-filled space inside the eye between the iris and the cornea's innermost surface) is a sign of intraocular inflammation. A score of 0 indicates an absence of inflammation. One eye (study eye) contributed to the analysis.

    Time frame: Baseline, Week 9

  13. Percentage of Patients With Ocular Inflammation at Baseline and 7 Days Post-injection Following 3rd Mandated Intravitreal Injection - Anterior Chamber Flare

    Anterior chamber flare was assessed by the investigator during slit lamp examination and graded on a 5-point scale, with 0 = none; 1 = mild (trace to clearly noticeable, visible); 2 = moderate; 3 = marked; and 4 = severe. The presence of flare (increased protein levels) in the anterior chamber of the eye (the fluid-filled space inside the eye between the iris and the cornea's innermost surface) is a sign of intraocular inflammation. A score of 0 indicates an absence of inflammation. Proportion of patients is reported as a percentage. One eye (study eye) contributed to the analysis.

    Time frame: Baseline, Week 9

08

Results

Posted Jun 5, 2019

Participant flow

Patients were recruited and enrolled from 24 sites located in Australia.

Participant flow — Overall Study
MilestoneRanibizumab 0.5 mgAflibercept 2.0 mg
Started142139
Safety set141139
Full analysis set (fas)141137
Completed117108
Not completed2531
Withdrew: Adverse event1011
Withdrew: Death22
Withdrew: Lost to follow-up11
Withdrew: Physician decision13
Withdrew: Protocol deviation40
Withdrew: Site administration problems10
Withdrew: Subject withdrew consent614

Outcome measures

PrimaryMean Change in Square-root Area of Geographic Atrophy (GA) From Baseline to Month 24

Multimodal images of the eye were obtained by trained study site personnel and forwarded to an independent Central Reading Center, where the area of GA was measured. Area was treated as zero if GA was reported as absent (Overall determination of GA presence). Mean change from baseline in GA area was reported in square root-transformed data (mm). One eye (study eye) contributed to the analysis.

Time frame:
Baseline, Month 24
Reported as:
Mean · mm
Mean Change in Square-root Area of Geographic Atrophy (GA) From Baseline to Month 24
mmRanibizumab 0.5 mgAflibercept 2.0 mg
Baseline0.024 ± 0.09880.050 ± 0.2345
Change from Baseline at Month 240.363 ± 0.71050.285 ± 0.5392
Statistical analysis
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Mixed Models Analysis · p = 0.236 · Treatment effect: 0.08 · 95% CI -0.05 to 0.21Fixed effects: Baseline GA area, treatment, visit, treatment by visit. Random effect: Subject
SecondaryMean Change in Square-root Area of Geographic Atrophy From Baseline to Month 12

Multimodal images of the eye were obtained by trained study site personnel and forwarded to an independent Central Reading Center, where the area of GA was measured. Area was treated as zero if GA was reported as absent (Overall determination of GA presence). Mean change from baseline in GA area was reported in square root-transformed data (mm). One eye (study eye) contributed to the analysis.

Time frame:
Baseline, Month 12
Reported as:
Mean · mm
Mean Change in Square-root Area of Geographic Atrophy From Baseline to Month 12
mmRanibizumab 0.5 mgAflibercept 2.0 mg
Baseline0.024 ± 0.09880.050 ± 0.2345
Change from Baseline at Month 120.155 ± 0.42720.145 ± 0.3179
Statistical analysis
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Mixed Models Analysis · p = 0.769 · Treatment effect: 0.02 · 95% CI -0.11 to 0.15Fixed effects: Baseline GA area, treatment, visit, treatment by visit. Random effect: Subject
SecondaryPercentage of Patients With Newly Developed Geographic Atrophy During the Overall 24 Months of the Study

Multimodal images of the eye were obtained by trained study site personnel and forwarded to an independent Central Reading Center. A patient was considered to have developed new GA if they did not have any GA at the start of the study period and were subsequently diagnosed with GA during the study period (diagnosis of GA change from "No" to "Yes)." The analysis of new GA development was restricted to only those subjects without GA reported at baseline. One eye (study eye) contributed to the analysis.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Number · percentage of patients
Percentage of Patients With Newly Developed Geographic Atrophy During the Overall 24 Months of the Study
percentage of patientsRanibizumab 0.5 mgAflibercept 2.0 mg
Baseline to Month 1217.620.3
Month 12 to Month 2415.17.2
Baseline to Month 2428.825.4
Statistical analysis
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Regression, Logistic · p = 0.586 · Odds ratio (or): 0.84 · 95% CI 0.44 to 1.59Odds ratio of 'Newly Developed GA (Yes)' at between the two treatment groups at study visit
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Regression, Logistic · p = 0.110 · Odds ratio (or): 2.27 · 95% CI 0.83 to 6.22Odds ratio of 'Newly Developed GA (Yes)' at between the two treatment groups at study visit
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Regression, Logistic · p = 0.554 · Odds ratio (or): 1.19 · 95% CI 0.67 to 2.09Includes treatment as factor. Model: log(p/1-p) =Treatment
SecondaryMean Number of Intravitreal Injections From Baseline to Month 12 and to Month 24

The number of intravitreal injections was calculated. One eye (study eye) contributed to the analysis.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Mean · injections
Mean Number of Intravitreal Injections From Baseline to Month 12 and to Month 24
injectionsRanibizumab 0.5 mgAflibercept 2.0 mg
Baseline to Month 129.7 ± 2.789.7 ± 2.54
Month 12 to Month 248.9 ± 3.248.3 ± 3.56
Baseline to Month 2417.7 ± 6.4417.0 ± 6.3
Statistical analysis
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Negative Binomial Regression Model · p = 0.733 · Treatment effect: 0.99 · 95% CI 0.95 to 1.04Treatment effect: Injection frequency (rate) ratio of Ranibizumab vs. Aflibercept
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Negative Binomial Regression Model · p = 0.745 · Treatment effect: 1.01 · 95% CI 0.95 to 1.08Treatment effect: Injection frequency (rate) ratio of Ranibizumab vs. Aflibercept
SecondaryMean Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12 and to Month 24

Visual acuity was assessed with spectacles or other visual corrective devices in place using logMAR charts and recorded in number of letters correctly identified. BCVA change was defined as a change in letters correctly identified from the baseline assessment. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis

Time frame:
Baseline, Month 12, Month 24
Reported as:
Mean · letters
Mean Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12 and to Month 24
lettersRanibizumab 0.5 mgAflibercept 2.0 mg
Baseline65.3 ± 15.1065.1 ± 12.53
Change from Baseline at Month 126.9 ± 12.255.2 ± 12.83
Change from Baseline at Month 246.5 ± 14.385.3 ± 13.33
Statistical analysis
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Mixed Models Analysis · p = 0.079 · Treatment effect: 2.32 · 95% CI -0.27 to 4.92Treatment Effect: Ranibizumab minus Aflibercept
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Mixed Models Analysis · p = 0.151 · Treatment effect: 1.95 · 95% CI -0.71 to 4.61Treatment Effect: Ranibizumab minus Aflibercept
SecondaryMean Change in Central Subfield Foveal Thickness (CSFT) From Baseline to Month 12 and to Month 24

CSFT (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using Optical Coherence Tomography (OCT) and measured in micrometers. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis

Time frame:
Baseline, Month 12, Month 24
Reported as:
Mean · micrometers
Mean Change in Central Subfield Foveal Thickness (CSFT) From Baseline to Month 12 and to Month 24
micrometersRanibizumab 0.5 mgAflibercept 2.0 mg
Baseline468.2 ± 150.82483.5 ± 168.05
Change from Baseline at Month 12-147.2 ± 128.38-171.6 ± 150.12
Change from Baseline at Month 24-151.3 ± 133.37-181.7 ± 155.48
Statistical analysis
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Mixed Models Analysis · p = 0.294 · Treatment effect: 10.12 · 95% CI -8.82 to 29.06Treatment Effect: Ranibizumab minus Aflibercept
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Mixed Models Analysis · p = 0.225 · Treatment effect: 11.86 · 95% CI -7.35 to 31.07Treatment Effect: Ranibizumab minus Aflibercept
SecondaryPercentage of Patients Showing no Intraretinal Fluid (IRF)/Subretinal Fluid (SRF)

Intraretinal fluid and subretinal fluid was assessed using Optical Coherence Tomography (OCT) and recorded as Present/Absent. One eye (study eye) contributed to the analysis.

Time frame:
Month 2, Month 12, Month 24
Reported as:
Number · percentage of patients
Percentage of Patients Showing no Intraretinal Fluid (IRF)/Subretinal Fluid (SRF)
percentage of patientsRanibizumab 0.5 mgAflibercept 2.0 mg
Month 256.961.3
Month 1255.963.6
Month 2457.360.6
Statistical analysis
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Regression, Logistic · p = 0.461 · Odds ratio (or): 0.83 · 95% CI 0.51 to 1.35Odds ratio of no IRF/SRF present between the two treatment groups at study visit
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Regression, Logistic · p = 0.215 · Odds ratio (or): 0.72 · 95% CI 0.44 to 1.21Odds ratio of no IRF/SRF present between the two treatment groups at study visit
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Regression, Logistic · p = 0.616 · Odds ratio (or): 0.87 · 95% CI 0.51 to 1.48Odds ratio of no IRF/SRF present between the two treatment groups at study visit
SecondaryPercentage of Patients Showing Greater Than and Equal to 15 Letters Gain for BCVA From Baseline to Month 12 and to Month 24

Visual acuity was assessed with spectacles or other visual corrective devices in place using logMAR charts and recorded in number of letters correctly identified. A gain in letters correctly identified indicates an improvement in visual acuity, while a loss indicates a worsening. One eye (study eye) contributed to the analysis.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Number · percentage of patients
Percentage of Patients Showing Greater Than and Equal to 15 Letters Gain for BCVA From Baseline to Month 12 and to Month 24
percentage of patientsRanibizumab 0.5 mgAflibercept 2.0 mg
Change from Baseline at Month 1222.020.7
Change from Baseline at Month 2424.818.5
Statistical analysis
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Regression, Logistic · p = 0.891 · Odds ratio (or): 1.05 · 95% CI 0.53 to 2.08Odds ratio of BCVA change from baseline ≥15 letters between the two treatment groups at study visit
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Regression, Logistic · p = 0.206 · Odds ratio (or): 1.61 · 95% CI 0.77 to 3.35Odds ratio of BCVA change from baseline ≥15 letters between the two treatment groups at study visit
SecondaryPercentage of Patients Showing Less Than and Equal to 15 Letters Loss for BCVA From Baseline to Month 12 and to Month 24

Visual acuity was assessed with spectacles or other visual corrective devices in place using logMAR charts and recorded in number of letters correctly identified. A gain in letters correctly identified indicates an improvement in visual acuity, while a loss indicates a worsening. One eye (study eye) contributed to the analysis.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Number · percentage of patients
Percentage of Patients Showing Less Than and Equal to 15 Letters Loss for BCVA From Baseline to Month 12 and to Month 24
percentage of patientsRanibizumab 0.5 mgAflibercept 2.0 mg
Change from Baseline at Month 1296.995.0
Change from Baseline at Month 2494.094.4
Statistical analysis
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Regression, Logistic · p = 0.460 · Odds ratio (or): 1.63 · 95% CI 0.45 to 5.93Odds ratio of BCVA change from baseline ≥ -15 letters between the two treatment groups at study visit
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Regression, Logistic · p = 0.913 · Odds ratio (or): 0.94 · 95% CI 0.30 to 2.90Odds ratio of BCVA change from baseline ≥ -15 letters between the two treatment groups at study visit
SecondaryMean Number of Times a Patient Needed to Return to Monthly Intravitreal Injections Over 24 Months

The number of times the patient returned to a monthly injection interval (from an extended interval) at least once during the 24-month study was calculated. One eye (study eye) contributed to the analysis.

Time frame:
Month 24
Reported as:
Mean · occurrences
Mean Number of Times a Patient Needed to Return to Monthly Intravitreal Injections Over 24 Months
occurrencesRanibizumab 0.5 mgAflibercept 2.0 mg
Mean Number of Times a Patient Needed to Return to Monthly Intravitreal Injections Over 24 Months2.3 ± 1.282.3 ± 1.15
SecondaryMean Change in Vascular Endothelial Growth Factor (VEGF) Plasma Concentration From Baseline to 7 Days After the Second and 7 Days After the Third Mandated Intravitreal Injection of Treatment

Blood for VEGF plasma concentration analysis was collected at Baseline and again at 7 days after the injection at Week 4 and 7 days after the injection at Week 8.

Time frame:
Baseline, Week 5, Week 9
Reported as:
Mean · picogram/milliliter (pg/mL)
Mean Change in Vascular Endothelial Growth Factor (VEGF) Plasma Concentration From Baseline to 7 Days After the Second and 7 Days After the Third Mandated Intravitreal Injection of Treatment
picogram/milliliter (pg/mL)Ranibizumab 0.5 mgAflibercept 2.0 mg
Baseline44.29 ± 43.36941.88 ± 35.236
Change from Baseline at Week 5-0.48 ± 30.299-26.37 ± 36.220
Change from Baseline at Week 90.48 ± 35.125-25.14 ± 32.525
Statistical analysis
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Mixed Models Analysis · p = <0.001 · Treatment effect: 27.20 · 95% CI 21.44 to 32.95Treatment Effect: Ranibizumab minus Aflibercept
  • Ranibizumab 0.5 mg vs Aflibercept 2.0 mg · Mixed Models Analysis · p = <0.001 · Treatment effect: 28.88 · 95% CI 23.08 to 34.68Treatment Effect: Ranibizumab minus Aflibercept
SecondaryPercentage of Patients With Change in Retinal Nerve Fibre Thickness From Baseline to Month 12 and Month 24

Retinal nerve fibre thickness was assessed using Optical Coherence Tomography (OCT) and measured in micrometers. A negative change in value (i.e. thinner nerve fibre) indicates nerve damage. One eye (study eye) contributed to the analysis.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Number · percentage of patients
Percentage of Patients With Change in Retinal Nerve Fibre Thickness From Baseline to Month 12 and Month 24
percentage of patientsRanibizumab 0.5 mgAflibercept 2.0 mg
Month 12: Decrease from Baseline2.52.7
Month 12: No Change from Baseline96.797.3
Month 12: Increase from Baseline0.80
Month 24: Decrease from Baseline3.61.0
Month 24: No Change from Baseline96.497.9
Month 24: Increase from Baseline01.0
SecondaryPercentage of Patients With Ocular Inflammation at Baseline and 7 Days Post-injection Following 3rd Mandated Intravitreal Injection - Anterior Chamber Cells

Anterior cell grade was assessed by the Investigator during slit lamp examination and graded on a 5-point scale: Grade 0=0 cells; Grade 1=1 to 10 cells; Grade 2=11 to 20 cells; Grade 3=21 to 50 cells; Grade 4=\>50 cells. The presence of blood cells (red and white) in the anterior chamber of the eye (the fluid-filled space inside the eye between the iris and the cornea's innermost surface) is a sign of intraocular inflammation. A score of 0 indicates an absence of inflammation. One eye (study eye) contributed to the analysis.

Time frame:
Baseline, Week 9
Reported as:
Number · percentage of patients
Percentage of Patients With Ocular Inflammation at Baseline and 7 Days Post-injection Following 3rd Mandated Intravitreal Injection - Anterior Chamber Cells
percentage of patientsRanibizumab 0.5 mgAflibercept 2.0 mg
Baseline: Grade 099.398.5
Baseline: Grade 1+0.71.5
Baseline: Grade 2+00
Baseline: Grade 3+00
Baseline: Grade 4+00
Week 9: Grade 095.192.7
Week 9: Grade 1+4.97.3
Week 9: Grade 2+00
Week 9: Grade 3+00
Week 9: Grade 4+00
SecondaryPercentage of Patients With Ocular Inflammation at Baseline and 7 Days Post-injection Following 3rd Mandated Intravitreal Injection - Anterior Chamber Flare

Anterior chamber flare was assessed by the investigator during slit lamp examination and graded on a 5-point scale, with 0 = none; 1 = mild (trace to clearly noticeable, visible); 2 = moderate; 3 = marked; and 4 = severe. The presence of flare (increased protein levels) in the anterior chamber of the eye (the fluid-filled space inside the eye between the iris and the cornea's innermost surface) is a sign of intraocular inflammation. A score of 0 indicates an absence of inflammation. Proportion of patients is reported as a percentage. One eye (study eye) contributed to the analysis.

Time frame:
Baseline, Week 9
Reported as:
Number · percentage of patients
Percentage of Patients With Ocular Inflammation at Baseline and 7 Days Post-injection Following 3rd Mandated Intravitreal Injection - Anterior Chamber Flare
percentage of patientsRanibizumab 0.5 mgAflibercept 2.0 mg
Baseline: Grade 097.899.3
Baseline: Grade 1+2.20.7
Baseline: Grade 2+00
Baseline: Grade 3+00
Baseline: Grade 4+00
Week 9: Grade 094.392.7
Week 9: Grade 1+5.77.3
Week 9: Grade 2+00
Week 9: Grade 3+00
Week 9: Grade 4+00

Adverse events

Collected over Adverse events were collected for the duration of the individual's participation in the study (approximately 24 months).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.5 mg3/141 (2.1%)50/141 (35.5%)122/141 (86.5%)
Aflibercept 2.0 mg6/139 (4.3%)58/139 (41.7%)123/139 (88.5%)
Most frequent serious events
Showing 10 of 167
Most frequent serious events
EventRanibizumab 0.5 mgAflibercept 2.0 mg
Atrial fibrillation (Non-ocular)Cardiac disorders7/1410/139
Basal cell carcinoma (Non-ocular)Neoplasms benign, malignant and unspecified (incl cysts and polyps)7/1412/139
Pneumonia (Non-ocular)Infections and infestations4/1414/139
Urinary tract infection (Non-ocular)Infections and infestations2/1414/139
Squamous cell carcinoma (Non-ocular)Neoplasms benign, malignant and unspecified (incl cysts and polyps)4/1414/139
Cerebrovascular accident (Non-ocular)Nervous system disorders1/1413/139
Chest pain (Non-ocular)General disorders3/1412/139
Fall (Non-ocular)Injury, poisoning and procedural complications3/1411/139
Femoral neck fracture (Non-ocular)Injury, poisoning and procedural complications3/1412/139
Aphasia (Non-ocular)Nervous system disorders3/1410/139
Most frequent other events
Showing 10 of 166
Most frequent other events
EventRanibizumab 0.5 mgAflibercept 2.0 mg
Chest X-ray (Non-ocular)Investigations14/14120/139
Computerised tomogram (Non-ocular)Investigations6/14118/139
Eye pain (Left eye)Eye disorders10/14115/139
Urinary tract infection (Non-ocular)Infections and infestations11/14115/139
Fall (Non-ocular)Injury, poisoning and procedural complications11/14115/139
Nasopharyngitis (Non-ocular)Infections and infestations15/1418/139
Age-related macular degeneration (Right eye)Eye disorders10/14114/139
Cataract (Left eye)Eye disorders3/14114/139
Eye pain (Right eye)Eye disorders14/14113/139
Constipation (Non-ocular)Gastrointestinal disorders6/14113/139

Baseline characteristics

All patients randomized to treatment

Age, Continuous
Age, Continuous(years)Ranibizumab 0.5 mgAflibercept 2.0 mgTotal
Mean76.6 ± 8.578.7 ± 7.4577.7 ± 8.06
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 0.5 mgAflibercept 2.0 mgTotal
Female7276148
Male7063133
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ranibizumab 0.5 mgAflibercept 2.0 mgTotal
Caucasian132130262
Black African011
Asian8715
Other213
09

Study locations

22 sites
  • Novartis Investigative Site
    Albury, New South Wales 2640, Australia
  • Novartis Investigative Site
    Brookvale, New South Wales 2100, Australia
  • Novartis Investigative Site
    Chatswood, New South Wales 2067, Australia
  • Novartis Investigative Site
    Hurtsville, New South Wales 2220, Australia
  • Novartis Investigative Site
    Mona Vale, New South Wales, Australia
  • Novartis Investigative Site
    Parramatta, New South Wales 2150, Australia
  • Novartis Investigative Site
    Strathfield, New South Wales 2035, Australia
  • Novartis Investigative Site
    Strathfield, New South Wales 2135, Australia
  • Novartis Investigative Site
    Sydney, New South Wales 2000, Australia
  • Novartis Investigative Site
    Sydney, New South Wales AUSTRALIA, Australia
  • Novartis Investigative Site
    Westmead, New South Wales 2145, Australia
  • Novartis Investigative Site
    Caboolture, Queensland 4510, Australia
  • Novartis Investigative Site
    Redcliffe, Queensland 4020, Australia
  • Novartis Investigative Site
    South Brisbane, Queensland 4101, Australia
  • Novartis Investigative Site
    Southport, Queensland 4215, Australia
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    South Launceston, Tasmania 7249, Australia
  • Novartis Investigative Site
    Clayton, Victoria 3168, Australia
  • Novartis Investigative Site
    Malvern, Victoria 3144, Australia
  • Novartis Investigative Site
    Parkville,, Victoria 3065, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
  • Novartis Investigative Site
    Subiaco, Western Australia 6008, Australia
10

References and documents

Publications

  • Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020 May 5;5(5):CD012208. doi: 10.1002/14651858.CD012208.pub2. PubMed 32374423 ↗
  • Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol. 2019 Apr 1;137(4):372-379. doi: 10.1001/jamaophthalmol.2018.6776. PubMed 30676617 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2014 to primary completion in Nov 2017, 43 months.

Results were first posted in Jun 2019, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2014
First posted
May 2, 2014
StartActual
Apr 11, 2014
Primary completionActual
Nov 15, 2017
CompletionActual
Nov 15, 2017
Results first posted
Jun 5, 2019
Last update
Jun 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02130024
Responsible party
Sponsor
First posted
May 2, 2014
Start date
Apr 11, 2014
Primary completion
Nov 15, 2017
Completion
Nov 15, 2017
Results posted
Jun 5, 2019
Last update
Jun 5, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion